Sanoculis is an Israel-based company which develops and markets three novel surgical techniques for the treatment of Glaucoma: MIMS® (Minimally Invasive Micro Sclerostomy), inferonasal MIMS® (after failed Trab) and MINT™ (Minimally Invasive Nasal Trabeculostomy).
These techniques are simple, fast, and minimally invasive. They require no stitches, eye-patch, implant or stent and thus leave nothing behind. In addition, they can be easily combined with Cataract surgery. These techniques address all Glaucoma patients who need surgery, from mild to severe, using the same stent-less technology.
The MIMS® technology creates a drainage channel to reduce IOP, ensuring a long lasting safe and controlled fluid flow. During the surgery, a sclero-corneal drainage channel is created to reduce the intra-ocular pressure (IOP). The novelty of the solution is that the channel ensures long-lasting controlled fluid flow with minor complications. MIMS® consists of a disposable sterile tool and a multi-use external machine.
The CE-approved MIMS® and inferonasal MIMS® surgeries were launched in 2022 for commercial use in Europe and Israel. The FDA recently approved the commencement of a MIMS® study in the US.
In 2022, Bausch + Lomb made an equity investment in Sanoculis and has entered into an exclusive European Distribution Agreement for MIMS®.
Sanoculis’ meeting goals:
- Increase awareness of Sanoculis and its novel products;
- Discuss recent progress in EU post-market studies results;
- Network with potential partners.